Effects of homocysteine on endothelial nitric oxide production.

Hyperhomocysteinemia (HHCy) is an independent and graded cardiovascular risk factor. HHCy is prevalent in patients with chronic renal failure, contributing to the increased mortality rate. Controversy exists as to the effects of HHCy on nitric oxide (NO) production: it has been shown that HHCy both increases and suppresses it. We addressed this problem by using amperometric electrochemical NO detection with a porphyrinic microelectrode to study responses of endothelial cells incubated with homocysteine (Hcy) to the stimulation with bradykinin, calcium ionophore, or L-arginine. Twenty-four-hour preincubation with Hcy (10, 20, and 50 microM) resulted in a gradual decline in responsiveness of endothelial cells to the above stimuli. Hcy did not affect the expression of endothelial nitric oxide synthase (eNOS), but it stimulated formation of superoxide anions, as judged by fluorescence of dichlorofluorescein, and peroxynitrite, as detected by using immunoprecipitation and immunoblotting of proteins modified by tyrosine nitration. Hcy did not directly affect the ability of recombinant eNOS to generate NO, but oxidation of sulfhydryl groups in eNOS reduced its NO-generating activity. Addition of 5-methyltetrahydrofolate restored NO responses to all agonists tested but affected neither the expression of the enzyme nor formation of nitrotyrosine-modified proteins. In addition, a scavenger of peroxynitrite or a cell-permeant superoxide dismutase mimetic reversed the Hcy-induced suppression of NO production by endothelial cells. In conclusion, electrochemical detection of NO release from cultured endothelial cells demonstrated that concentrations of Hcy >20 microM produce a significant indirect suppression of eNOS activity without any discernible effects on its expression. Folates, superoxide ions, and peroxynitrite scavengers restore the NO-generating activity to eNOS, collectively suggesting that cellular redox state plays an important role in HCy-suppressed NO-generating function of this enzyme.

[1]  M. Goligorsky,et al.  Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. , 1999, American journal of physiology. Renal physiology.

[2]  T. Vanden Hoek,et al.  Role of reactive oxygen species in acetylcholine-induced preconditioning in cardiomyocytes. , 1999, The American journal of physiology.

[3]  B. Gewertz,et al.  Endothelial permeability and IL-6 production during hypoxia : role of ROS in signal transduction , 1999 .

[4]  J. Cazenave,et al.  Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Rabelink,et al.  Future for folates in cardiovascular disease , 1999, European journal of clinical investigation.

[6]  L. Bausserman,et al.  Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. , 1999, Journal of the American Society of Nephrology : JASN.

[7]  N. Dudman,et al.  Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo. , 1999, Circulation research.

[8]  Sae-Yong Hong,et al.  Plasma Homocysteine, Vitamin B6, Vitamin B12 and Folic Acid in End-Stage Renal Disease during Low-Dose Supplementation with Folic Acid , 1998, American Journal of Nephrology.

[9]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[10]  T. Johns,et al.  Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases , 1998, The Annals of pharmacotherapy.

[11]  J. Kastelein,et al.  5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. , 1998, Circulation.

[12]  A. Donker,et al.  No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  S. Vollset,et al.  Homocysteine and cardiovascular disease. , 1998, Annual review of medicine.

[14]  M. Mann,et al.  Future horizons in cardiovascular molecular therapeutics. , 1997, The American journal of cardiology.

[15]  D. Mark.  Economics of treating heart failure. , 1997, The American journal of cardiology.

[16]  J. Loscalzo,et al.  Stimulation of endothelial nitric oxide production by homocyst(e)ine. , 1997, Atherosclerosis.

[17]  J. Loscalzo,et al.  Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.

[18]  A. Bostom,et al.  Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. , 1997, Kidney international.

[19]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[20]  J. Thompson,et al.  Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Loscalzo.  The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[22]  F. Fang,et al.  Homocysteine Antagonism of Nitric Oxide-Related Cytostasis in Salmonella typhimurium , 1996, Science.

[23]  W. Sessa,et al.  Characterization of bovine endothelial nitric oxide synthase expressed in E. coli. , 1996, Biochemical and biophysical research communications.

[24]  S. Liochev,et al.  A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.

[25]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[26]  T. Lüscher,et al.  Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. , 1995, The Journal of clinical investigation.

[27]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[28]  A. Quyyumi,et al.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. , 1995, The Journal of clinical investigation.

[29]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .

[31]  S. Thom,et al.  Nitric oxide released by platelets inhibits neutrophil B2 integrin function following acute carbon monoxide poisoning. , 1994, Toxicology and applied pharmacology.

[32]  P. Kubes,et al.  Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. , 1994, Circulation research.

[33]  A. Koch,et al.  Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Klahr,et al.  L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. , 1994, Kidney international.

[35]  J. Hodgson,et al.  Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. , 1994, Journal of the American College of Cardiology.

[36]  B. Tönshoff,et al.  Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. , 1994, Kidney international.

[37]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[39]  H. Drexler,et al.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. , 1991, Circulation.

[40]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[41]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[42]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[43]  R. Matthews,et al.  Characterization of the dihydropterin reductase activity of pig liver methylenetetrahydrofolate reductase. , 1980, The Journal of biological chemistry.

[44]  K. Mccully,et al.  Homocysteine theory of arteriosclerosis. , 1975, Atherosclerosis.

[45]  K. Mccully,et al.  Homocysteine Metabolism in Scurvy, Growth and Arteriosclerosis , 1971, Nature.